Regulation of astrocyte functions in multiple sclerosis

Cold Spring Harbor Perspectives in Medicine

Volumn 9, Issue 1, 2019, Pages

  Wheeler, Michael A ^a   Quintana, Francisco J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; SPHINGOLIPID; CYTOKINE;

ARTICLE; ASTROCYTE; CELL FUNCTION; CELL HETEROGENEITY; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; SPHINGOLIPID METABOLISM; CYTOTOXICITY; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ASTROCYTES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MULTIPLE SCLEROSIS; SIGNAL TRANSDUCTION;

EID: 85053297682     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a029009     Document Type: Article

References (95)

1. Allen NJ, Barres BA. 2009. Neuroscience: Glia—More than just brain glue. Nature 457: 675–677.
2. Allen NJ, Bennett ML, Foo LC, Wang GX, Chakraborty C, Smith SJ, Barres BA. 2012. Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature 486: 410–414.
3. Anderson MA, Ao Y, Sofroniew MV. 2014. Heterogeneity of reactive astrocytes. Neurosci Lett 565: 23–29.
4. Anderson MA, Burda JE, Ren Y, Ao Y, O’Shea TM, Kawaguchi R, Coppola G, Khakh BS, Deming TJ, Sofroniew MV. 2016. Astrocyte scar formation aids central nervous system axon regeneration. Nature 532: 195–200.
5. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK. 2010. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11: 854–861.
6. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. 2007. High-resolution profiling of histone methylations in the human genome. Cell 129: 823–837.
7. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M, et al. 2008. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 118: 1532–1543.
8. Bayraktar OA, Fuentealba LC, Alvarez-Buylla A, Rowitch DH. 2014. Astrocyte development and heterogeneity. Cold Spring Harb Perspect Biol 7: a020362.
9. Ben Haim L, Rowitch DH. 2017. Functional diversity of astrocytes in neural circuit regulation. Nat Rev Neurosci 18: 31–41.
10. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Bicciato S, Mazza EM, Macchiarulo A, Vacca C, et al. 2014. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 511: 184–190.
11. Blanco-Suarez E, Caldwell AL, Allen NJ. 2017. Role of astro-cyte-synapse interactions in CNS disorders. J Physiol 595: 1903–1916.
12. Brancaccio M, Patton AP, Chesham JE, Maywood ES, Hastings MH. 2017. Astrocytes control circadian timekeeping in the suprachiasmatic nucleus via glutamatergic signaling. Neuron 93: 1420–1435.e1425.
13. Bruck W, Vollmer T. 2013. Multiple sclerosis: Oral laquinimod for MS—Bringing the brain into focus. Nat Rev Neurol 9: 664–665.
14. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. 2013. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods 10: 1213–1218.
15. Buffington SA, Di Prisco GV, Auchtung TA, Ajami NJ, Petrosino JF, Costa-Mattioli M. 2016. Microbial reconstitu-tion reverses maternal diet-induced social and synaptic deficits in offspring. Cell 165: 1762–1775.
16. Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW. 2016. Translating RNA sequencing into clinical diagnostics: Opportunities and challenges. Nat Rev Genet 17: 257–271.
17. Chang CY, Puga A. 1998. Constitutive activation of the aromatic hydrocarbon receptor. Mol Cell Biol 18: 525–535.
18. Charcot JM. 1868. Histologie de la sclérose en plaque [His-tology of multiple sclerosis]. Gaz des Hôpitaux 41: 554– 555.
19. Chatterjee S, Alsaeedi N. 2012. Lactosylceramide synthase as a therapeutic target to mitigate multiple human diseases in animal models. Adv Exp Med Biol 749: 153–169.
20. Christopherson KS, Ullian EM, Stokes CC, Mullowney CE, Hell JW, Agah A, Lawler J, Mosher DF, Bornstein P, Barres BA. 2005. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 120: 421–433.
21. Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, et al. 2013. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504: 394–400.
22. Dallerac G, Rouach N. 2016. Astrocytes as new targets to improve cognitive functions. Prog Neurobiol 144: 48–67.
23. De Keyser J, Laureys G, Demol F, Wilczak N, Mostert J, Clinckers R. 2010. Astrocytes as potential targets to suppress inflammatory demyelinating lesions in multiple sclerosis. Neurochem Int 57: 446–450.
24. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL. 2009. Toll-like receptor 2 and poly (ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 10: 958–964.
25. Farez MF, Fiol MP, Gaitan MI, Quintana FJ, Correale J. 2015a. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 86: 26–31.
26. Farez MF, Mascanfroni ID, Mendez-Huergo SP, Yeste A, Murugaiyan G, Garo LP, Balbuena Aguirre ME, Patel B, Ysrraelit MC, Zhu C, et al. 2015b. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell 162: 1338–1352.
27. Farez MF, Calandri IL, Correale J, Quintana FJ. 2016. Anti-inflammatory effects of melatonin in multiple sclerosis. BioEssays 38: 1016–1026.
28. Flavell SW, Greenberg ME. 2008. Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system. Annu Rev Neurosci 31: 563–590.
29. Gabriely G, Wheeler MA, Takenaka MC, Quintana FJ. 2017. Role of AHR and HIF-1alpha in glioblastoma metabolism. Trends Endocrinol Metab 28: 428–436.
30. Gacias M, Gaspari S, Santos PM, Tamburini S, Andrade M, Zhang F, Shen N, Tolstikov V, Kiebish MA, Dupree JL, et al. 2016. Microbiota-driven transcriptional changes in prefrontal cortex override genetic differences in social behavior. eLife 5: 13442.
31. + regulatory T cells. Nat Immunol 11: 846–853.
32. Goverman J. 2009. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9: 393–407.
33. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli JA, Chow J, Reisman SE, Petrosino JF, et al. 2013. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155: 1451–1463.
34. Husemann J, Loike JD, Anankov R, Febbraio M, Silverstein SC. 2002. Scavenger receptors in neurobiology and neu-ropathology: Their role on microglia and other cells of the nervous system. Glia 40: 195–205.
35. Jaitin DA, Kenigsberg E, Keren-Shaul H, Elefant N, Paul F, Zaretsky I, Mildner A, Cohen N, Jung S, Tanay A, et al. 2014. Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 343: 776–779.
36. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, et al. 2016. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun 7: 12015.
37. Johnson DS, Mortazavi A, Myers RM, Wold B. 2007. Genome-wide mapping of in vivo protein-DNA interactions. Science 316: 1497–1502.
38. Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, et al. 2016. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proc Natl Acad Sci 113: E6145–E6152.
39. Khakh BS, Sofroniew MV. 2015. Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci 18: 942–952.
40. Klein AM, Mazutis L, Akartuna I, Tallapragada N, Veres A, Li V, Peshkin L, Weitz DA, Kirschner MW. 2015. Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 161: 1187–1201.
41. Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Nativi-dad JM, et al. 2016. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 22: 598–605.
42. Lassmann H. 2014. Mechanisms of white matter damage in multiple sclerosis. Glia 62: 1816–1830.
43. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Boh-len CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, et al. 2017. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541: 481–487.
44. Lin CCJ, Yu K, Hatcher A, Huang TW, Lee HK, Carlson J, Weston MC, Chen F, Zhang Y, Zhu W, et al. 2017. Identification of diverse astrocyte populations and their malignant analogs. Nat Neurosci 20: 396–405.
45. Ludwin SK, Rao V, Moore CS, Antel JP. 2016. Astrocytes in multiple sclerosis. Mult Scler 22: 1114–1124.
46. Luhder F, Kebir H, Odoardi F, Litke T, Sonneck M, Alvarez JI, Winchenbach J, Eckert N, Hayardeny L, Sorani E, et al. 2017. Laquinimod enhances central nervous system barrier functions. Neurobiol Dis 102: 60–69.
47. Ma Z, Stork T, Bergles DE, Freeman MR. 2016. Neuro-modulators signal through astrocytes to alter neural circuit activity and behaviour. Nature 539: 428–432.
48. Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, Tirosh I, Bialas AR, Kamitaki N, Martersteck EM, et al. 2015. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161: 1202–1214.
49. Mascanfroni ID, Takenaka MC, Yeste A, Patel B, Wu Y, Kenison JE, Siddiqui S, Basso AS, Otterbein LE, Pardoll DM, et al. 2015. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat Med 21: 638–646.
50. Matikainen T, Perez GI, Jurisicova A, Pru JK, Schlezinger JJ, Ryu HY, Laine J, Sakai T, Korsmeyer SJ, Casper RF, et al. 2001. Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals. Nat Genet 28: 355–360.
51. Mayo L, Trauger SA, Blain M, Nadeau M, Patel B, Alvarez JI, Mascanfroni ID, Yeste A, Kivisakk P, Kallas K, et al. 2014. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med 20: 1147–1156.
52. Metzker ML. 2010. Sequencing technologies—The next generation. Nat Rev Genet 11: 31–46.
53. Mayo L, Cunha AP, Madi A, Beynon V, Yang Z, Alvarez JI, Prat A, Sobel RA, Kobzik L, Lassmann H, et al. 2016. IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation. Brain 139: 1939–1957.
54. Meyer CA, Liu XS. 2014. Identifying and mitigating bias in next-generation sequencing methods for chromatin biology. Nat Rev Genet 15: 709–721.
55. Mimran A, Mor F, Carmi P, Quintana FJ, Rotter V, Cohen IR. 2004. DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response. J Clin Invest 113: 924–932.
56. Molofsky AV, Kelley KW, Tsai HH, Redmond SA, Chang SM, Madireddy L, Chan JR, Baranzini SE, Ullian EM, Rowitch DH. 2014. Astrocyte-encoded positional cues maintain sensorimotor circuit integrity. Nature 509: 189–194.
57. Nair A, Frederick TJ, Miller SD. 2008. Astrocytes in multiple sclerosis: A product of their environment. Cell Mol Life Sci 65: 2702–2720.
58. + T cells. Science 327: 1098–1102.
59. Palma JA, Pagola I. 2012. Oral laquinimod for multiple sclerosis. N Engl J Med 366: 2527; author reply 2527–2528.
60. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, et al. 2005. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310: 850–855.
61. Quintana FJ. 2013a. The aryl hydrocarbon receptor: A molecular pathway for the environmental control of the immune response. Immunology 138: 183–189.
62. Quintana FJ. 2013b. Regulation of central nervous system autoimmunity by the aryl hydrocarbon receptor. Semin Immunopathol 35: 627–635.
63. Quintana FJ. 2014. LeA(H)Rning self-control. Cell Res 24: 1155–1156.
64. Quintana FJ, Sherr DH. 2013. Aryl hydrocarbon receptor control of adaptive immunity. Pharmacolog Rev 65: 1148–1161.
65. Rotem A, Ram O, Shoresh N, Sperling RA, Goren A, Weitz DA, Bernstein BE. 2015. Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. Nat Biotechnol 33: 1165–1172.
66. Rothhammer V, Quintana FJ. 2015. Control of autoimmune CNS inflammation by astrocytes. Semin Immunopathol 37: 625–638.
67. Rothhammer V, Quintana FJ. 2016. Environmental control of autoimmune inflammation in the central nervous system. Curr Opin Immunol 43: 46–53.
68. Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, Chao CC, Patel B, Yan R, Blain M, et al. 2016. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 22: 586–597.
69. Rothhammer V, Borucki DM, Garcia Sanchez MI, Mazzola MA, Hemond CC, Regev K, Paul A, Kivisäkk P, Bakshi R, Izquierdo G, et al. 2017a. Dynamic regulation of serum aryl hydrocarbon receptor agonists in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 4: e359.
70. Rothhammer V, Kenison JE, Tjon E, Takenaka MC, de Lima KA, Borucki DM, Chao CC, Wilz A, Blain M, Healy L, et al. 2017b. Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation. Proc Natl Acad Sci 114: 2012–2017.
71. Sanz E, Yang L, Su T, Morris DR, McKnight GS, Amieux PS. 2009. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc Natl Acad Sci 106: 13939–13944.
72. Seifert G, Schilling K, Steinhauser C. 2006. Astrocyte dysfunction in neurological disorders: A molecular perspective. Nat Rev Neurosci 7: 194–206.
73. Sharma P, Allison JP. 2015. The future of immune checkpoint therapy. Science 348: 56–61.
74. Shemer A, Erny D, Jung S, Prinz M. 2015. Microglia plasticity during health and disease: An immunological perspective. Trends Immunol 36: 614–624.
75. Shendure J, Ji H. 2008. Next-generation DNA sequencing. Nat Biotechnol 26: 1135–1145.
76. Silver J, Miller JH. 2004. Regeneration beyond the glial scar. Nat Rev Neurosci 5: 146–156.
77. Sofroniew MV. 2015. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci 16: 249–263.
78. Sofroniew MV, Vinters HV. 2010. Astrocytes: Biology and pathology. Acta Neuropathol 119: 7–35.
79. –/– mice in brain slices and during startle responses in vivo. Nat Neurosci 18: 708–717.
80. Steinman L. 2009. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 9: 440–447.
81. Steinman L. 2014. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol 32: 257–281.
82. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, et al. 2007. The classical complement cascade mediates CNS synapse elimination. Cell 131: 1164–1178.
83. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. 2014. The aryl hydrocarbon receptor: Multitasking in the immune system. Annu Rev Immunol 32: 403–432.
84. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. 2012. Will the real multiple sclerosis please stand up? Nat Rev Neurosci 13: 507–514.
85. Takenaka MC, Robson S, Quintana FJ. 2016. Regulation of the T cell response by CD39. Trends Immunol 37: 427– 439.
86. Tao Y, Rotem A, Zhang H, Chang CB, Basu A, Kolawole AO, Koehler SA, Ren Y, Lin JS, Pipas JM, et al. 2015. Rapid, targeted and culture-free viral infectivity assay in drop-based microfluidics. Lab Chip 15: 3934–3940.
87. Toft-Hansen H, Fuchtbauer L, Owens T. 2011. Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease. Glia 59: 166–176.
88. Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U. 2014. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol 262: 66–71.
89. Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL, Group BS. 2014. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 261: 773–783.
90. Voskuhl RR, Peterson RS, Song B, Ao Y, Morales LB, Tiwari-Woodruff S, Sofroniew MV. 2009. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 29: 11511–11522.
91. Wu HY, Quintana FJ, da Cunha AP, Dake BT, Koeglsperger T, Starossom SC, Weiner HL. 2011. In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS ONE 6: e23618.
92. Xie L, Yang SH. 2015. Interaction of astrocytes and T cells in physiological and pathological conditions. Brain Res 1623: 63–73.
93. Yeste A, Takenaka MC, Mascanfroni ID, Nadeau M, Kenison JE, Patel B, Tukpah AM, Babon JA, DeNicola M, Kent SC, et al. 2016. Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2. Sci Signal 9: ra61.
94. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA. 2012. Genomic analysis of reactive astrogliosis. J Neurosci 32: 6391–6410.
95. Zhang I, Alizadeh D, Liang J, Zhang L, Gao H, Song Y, Ren H, Ouyang M, Wu X, D’Apuzzo M, et al. 2016. Characterization of arginase expression in glioma-associated microglia and macrophages. PLoS ONE 11: e0165118.